Confronting the degeneracy of convergent combinatorial immunogens, or 'mixotopes', with the specificity of recognition of the target sequences

Vaccine

Volumn 15, Issue 14, 1997, Pages 1568-1578

  Gras Masse, H ^a   Boutillon, C ^a   Diesis, E ^a   Deprez, B ^a   Tartar, A ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Convergent peptide libraries; Mixotopes; Serological cross reactivity; V3 loop peptide

Indexed keywords

ANTIGEN; PEPTIDE; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CROSS REACTIONS; FEMALE; HIV ENVELOPE PROTEIN GP120; IMMUNE SERA; IMMUNIZATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS;

EID: 0030756762     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00079-0     Document Type: Article

References (17)

1. Rusche, J.R., Javahrian, K., McDanal, C., Petro, J., Lynn, D.L., Grimaila, R., Langlois, R.C., Arthur, L.O., Fishinger, P.J., Putney, S.D. and Matthews, T.J. Proceedings of the National Academy of Sciences of the United States of America 1988, 85, 3198-3202.
2. Gras-Masse, H., Ameisen, J.C., Boutillon, C., Rouaix, F., Bossus, M., Deprez, B., Neyrinck, J-L., Capron, A. and Tartar, A. Synthetic vaccines and HIV-1 hypervariability: a 'mixotope' approach. Peptide Research 1992, 4, 211-216.
3. Estaquier, J., Gras-Masse, H., Boutillon, C., Ameisen, J-C., Capron, A., Tartar, A. and Auriault, C. The mixotope: a combinatorial peptide library as a T cell B immunogen. European Journal of Immunology 1993, 24, 2789-2795.
4. Estaquier, J., Boutillon, C., Georges, B., Ameisen, J-C., Tartar, A. and Auriault, C. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses. Journal of Peptide Science 1996, 2, 165-175.
5. Anderson, D.E., Malley, A., Benjamini, E., Gardner, M.B. and Torres, J.V. Hypervariable epitope constructs as a means of accounting for epitope variability. Vaccine 1994, 12, 736.
6. Tam, J.P., Heath, W.F. and Merrifield, R.B. SN2 deprotection of synthetic peptides with a low concentration of HF in dimethyl sulfide: evidence and application in peptide synthesis. Journal of American Chemistry Society 1983, 105, 6442-6455.
7. Vranken, W.F., Budenski, M., Martins, J., Fant, F., Boulez, K., Gras-Masse, H. and Borremans, F.A. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. European Journal of Biochemistry 1996, 236, 100-108.
8. Vranken, W.F., Budenski, J., Fant, F., Boulez, K., Gras-Masse, H. and Borremans, F.A. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the ELI HIV-1 strain in water. Collection of Czechoslovak Chemical Communications 1996, 61, 742-750.
9. Geysen, H., Mason, T.J. and Rodda, S.J. Cognitive features of continuous antigenic determinants. Journal of Molecular Recognition 1988, 1, 32-41.
10. LaRosa, G., Davide, J., Weinhold, K., Waterbury, J., Profy, A., Lewis, J., Langlois, A., Dreesman, G., Neal, R., Bobswell, R.N., Shadduck, P., Holley, L., Karplus, M., Bolognesi, D., Matthews, T., Emini, E. and Putney, S. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249, 932-935.
11. Furka, A., Sebestyen, F., Asgedom, M. and Dibo, G. General method for rapid synthesis of multicomponent peptide mixtures. International Journal of Peptide and Protein Research 1991, 37, 487-493.
12. Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J., Kazmierski, W.M. and Knapp, R.J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991, 354, 82-84.
13. Gaillard, J.L., Bercehe, P., Frehel, C., Gouin, E. and Cossart, P. Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive. Cell 1991, 65, 1127-1141.
14. Neurath, A.R. and Strick, N. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1). Molecular Immunology 1990, 27, 539-549.
15. Boudet, F., Girard, M., Theze, J. and Zouali, M. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120. International Immunology 1992, 4, 283-284.
16. Moore, J.P., Cao, Y., Leu, J., Qin, L., Korber, B. and Ho, D.D. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology 1996, 70, 427-440.
17. Klinman, D.M., Higgins, K.W. and Conover, J. Sequential immunizations with rgp120 from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly cross-reactive T-cells. Journal of Experimental Medicine 1991, 173, 881-886.